[Neurodegenerative disorders and the role of trinucleotide repeat expansion. II. Molecular genetics].

N. Knoers,N. H. Kremer

Abstract:

What problem does this paper attempt to address?

HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIa trial.

Lijuan Chen,Linyu Yang,Jie Wang,Rui Liang,He Li,Mengke Liu,Yi Wen,Lin Liu,Xiaoqiong Tang,Jieping Li,Xun Lai,Huijing Wu,Yajun Li,Shihua Huang,Lihua Yang,Ke Tan,Li Wang,Ting Niu,Weili Zhao

DOI: https://doi.org/10.1200/jco.2024.42.17_suppl.lba7074

IF: 45.3

2024-06-06

Journal of Clinical Oncology

Abstract:LBA7074 Background: Relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) has a poor prognosis. Double-expressor (DEL) or TP53 abnormal r/r DLBCL patients(pts) are associated with even worse outcomes. Class I and IIb histone deacetylases (HDACs) are overexpressed in DLBCL and have been identified as a therapy target. Purinostat Mesylate (PM) is a high selective HDAC I/IIb inhibitor. Phase I dose-escalation trial of PM (1.2, 2.4, 4.0, 6.0, 8.4, 11.2, 15 mg/m 2 ) by i.v was conducted in 29 hematologic malignancies at day 1, 4, 8, 11 of a 21-day cycle. PM was generally well tolerated with no DLTs. 61.1% (11/18) ORR was observed in r/r lymphoma pts. Based on these data, we conducted a phase 2a to further explore efficacy and safety of PM and mechanism of actions. Methods: This randomized, multicenter, open-label, phase 2a study was conducted from Nov.2022 to the present(NCT05563844). Key eligibility include r/r DLBCL pts with prior therapy including anti-CD20 antibody and anthracycline-based chemotherapy; ECOG≤2. Thirty pts were randomized 1:1 received PM at 8.4 and 11.2 mg/m 2 on Day 1, 4, 8, 11 of a 21-day cycle. Pts continued to receive PM until disease progression or unacceptable toxicity. Primary outcome was ORR and safety. Multiple cell lines and PDX mouse models were used to evaluate the PM activity and mechanism of action in vitro and in vivo. ATAC-seq, bulk RNA-seq, and scRNA-seq from both PDX models and pts were investigated for the activated immune response of PM. Results: Thirty patients were enrolled and 28 patients were evaluable. The ORR (20/28) was 71.4% (95%CI:51.3-86.8) with 5 CR and 15 PR. Fifteen pts at 8.4 mg/m 2 achieved an ORR of 66.7%(95%CI:38.4-88.2) with 1 CR and 9 PR. Thirteen pts at 11.2 mg/m 2 achieved ORR of 76.9%(95%CI:46.2-95.0) with 4 CR and 6 PR. As of the data cut off in Feb. 2024, 7 pts remained on treatment and the longest treatment has lasted 17 cycles. Median PFS was 4.3m (95%CI:2.8-8.5), OS were immature. In subgroup analyses, 7 DE DLBCL pts obtained 42.9%(3/7) ORR and 11 pts with TP53 abnormal by FISH or NGS test achieved 45.5%(5/11) ORR. Fifteen pts with non-DE or without TP53 abnormal achieved ORR of 86.7%(13/15). The most frequently reported Grade≥3 TRAE were thrombocytopenia, neutropenia, lymphocytopenia. No PM-related death was reported. PM monotherapy showed stronger and superior antitumor effects in DE DLBCL and TP53 mutations PDX models than selinexor and R-CHOP. PM significantly down-regulates the proteins c-MYC, EZH2, and mutated P53. ATAC-seq, bulk RNA-seq and scRNA-seq revealed that PM can stimulate the proliferation and activation of cytotoxic T cells and NKT cells, up-regulate the expression of B-cell tumor MHC I and II and inhibit tumor cell immune escape. Conclusions: This study further supports the recommended dose 11.2 mg/m 2 PM as the phase 2b for r/r DLBCL. Currently, the phase 2b, open-label, multicenter study has enrolled in 37 sites in China. Clinical trial information: NCT05563844 .

oncology
Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model

Zejiang Zhu,Jiaolin Wen,Yaohui Xu,Heying Pei,Dan Li,Minghai Tang,Peng Bai,Jun He,Zhuang Yang,Lijuan Chen

DOI: https://doi.org/10.1080/07853890.2022.2045347

IF: 5.348

2022-03-04

Annals of Medicine

Abstract:Background: Previous studies have proven that Purinostat Mesylate (PM) is a new HDAC inhibitor and exhibits significant antitumor efficacy. However, the clinical application of PM was greatly limited by its poor solubility in water and low bioavailability.Objective:To increase the solubility of PM through pharmaceutical research, and prepare it into an injection that meets the needs of intravenous use to promote its clinical application.MethodsThe prepared PM/HP-β-CD inclusion complex was studied by computer simulation, fourier transform infrared spectroscopy (FT-IR), nuclear magnetic resonance (1H-NMR spectroscopy), and scanning electron microscopy (SEM). Then, the antitumor effects of PM/HP-β-CD inclusion complex were studied by in vitro cytotoxicity assay, apoptosis assay, pharmacokinetic study and in vivo antitumor assay.Results:Phase Solubility Analysis revealed that PM and HP-β-CD were compatible and the solubility of PM increased almost 220 times, to 2.02 mg/mL. The interaction mechanism studies revealed that PM could be embedded into the cavity of HP-β-CD through the side of the aminobenzene ring. Cell viability and apoptosis assays showed that PM/HP-β-CD complex maintained the good anti-cancer activity of PM, and PM/HP-β-CD complex has a better anti-tumor effect and lower toxicity than LBH589 and Hyper-CVAD/RTX in vivo. All the results suggest that HP-β-CD can solve the problem of PM administration and provide a way for clinical application of PM.Conclusions: In this study, an injectable formulation of PM in HP-β-CD (10% w/v) was prepared to improve its water solubility. Our research provides a way for clinical administration of PM, which has been under phase I clinical trial for the treatment of relapsed or refractory B-cell-related hematologic malignancies in China and the USA.KEY MESSAGESWe developed a preparation of Purinostat Mesylate that can be administered intravenously, reducing the toxicity associated with oral administration.This preparation has an outstanding therapeutic effect on SU-DHL-6 xenograft tumour, indicating its clinical value, which has been under phase I clinical trial for the treatment of relapsed or refractory B-cell-related haematologic malignancies in China and the USA.

medicine, general & internal
The Novel Histone Deacetylase Inhibitor Pracinostat Suppresses the Malignant Phenotype in Human Glioma

Chen Mantao,Zhang Luyuan,Zhan Renya,Zheng Xiujue

DOI: https://doi.org/10.1007/s11033-022-07559-y

IF: 2.7422

2022-01-01

Molecular Biology Reports

Abstract:INTRODUCTION:Glioma is the most common malignant brain tumor in adults. The effects of conventional treatment regimens are still limited to prolonging the survival of patients. Histone deacetylases (HDACs) are potential targets for tumor treatment. Pracinostat is a new type of HDAC inhibitor (HDACi) that has a significant antitumor effect on a variety of tumors. Thus, we aim to investigate the role of pracinostat in human glioma and explored its underlying mechanism.METHODS:Cell viability, proliferation and apoptosis of human glioma cell lines were measured by Cell Counting kit 8 and flow cytometry. Pathway verification and protein interaction were determined by quantitative real-time polymerase chain reaction, Western blotting and immunofluorescence staining. Transwell technology was used to assess the migration and invasion of cells. Clinical significance of TIMP3, MMP9 and MMP2 in glioma was analyzed through The Cancer Genome Atlas (TCGA) database and the Genotype-Tissue Expression (GTEx) database.RESULTS:Functionally, pracinostat not only inhibited proliferation and induced apoptosis but also inhibited migration and invasion in human glioma cell lines. Mechanistically, pracinostat increased the expression of TIMP3 and decreased the expression of MMP2, MMP9 and VEGF in human glioma cells in vitro and in vivo. In addition, pracinostat inhibited both the PI3K/Akt signaling pathway and the STAT3 pathway.CONCLUSIONS:Our results strongly support the potential clinical use of pracinostat as a novel therapy for human glioma in the near future.
HDAC I/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells

Qiang Qiu,Linyu yang,Yunyu Feng,Zejiang Zhu,Ning Li,Li Zheng,Yuanyuan Sun,Cong Pan,Huandi Qiu,Xue Cui,Wei He,Fang Wang,Yuyao Yi,Minghai Tang,Zhuang Yang,Yunfan Yang,Zhihui Li,Lijuan Chen,Yiguo Hu

DOI: https://doi.org/10.1016/j.bioactmat.2022.08.006

IF: 18.9

2022-09-21

Bioactive Materials

Abstract:Highlights • PM is a novel HDACI/IIb inhibitor with better selectivity and inhibitory activity than currently marketed HDAC inhibitors. • PMF completely overcomes the problem of PM's poor solubility, and improved PM stability and pharmacokinetic properties. • PMF effectively inhibits disease progression and abrogates leukemia stem cells survival in TKI-resistant CML mouse model. • Simultaneous targeting of I/IIb HDACs and glutaminolysis could sufficiently eradicated LSCs in the mouse model. Purinostat Mesylate (PM) is a novel highly selective and active HDAC I/IIb inhibitor, and the injectable formulation of PM (PMF) based on the compound prescription containing cyclodextrin completely can overcome PM's poor solubility and improves its stability and pharmacokinetic properties. Here, we showed that PM effectively repressed the survival of Ph + leukemia cells and CD34 + leukemia cells from CML patients in vitro . In vivo studies demonstrated that PMF significantly prevented BCR-ABL(T315I) induced CML progression by restraining leukemia stem cells (LSCs), which are insensitive to chemotherapy and responsible for CML relapse. Mechanism studies revealed that targeting HDAC I/IIb repressed several important factors for LSCs survival including c-Myc, β-Catenin, E2f, Ezh2, Alox5, and mTOR, as well as interrupted some critical biologic processes. Additionally, PMF increased glutamate metabolism in LSCs by increasing GLS1. The combination of PMF and glutaminase inhibitor BPTES synergistically eradicated LSCs by altering multiple key proteins and signaling pathways which are critical for LSC survival and self-renewal. Overall, our findings represent a new therapeutic strategy for eliminating LSCs by targeting HDAC I/IIb and glutaminolysis, which potentially provides a guidance for PMF clinical trials in the future for TKI resistance CML patients. Graphical abstract The presence of leukemia stem cells and TKI treatment resistance are the root causes why CML disease cannot be cured. PM, the novel highly selective HDAC I/IIb inhibitor. We prepared the free PM into the injectable formulation of PM (PMF) based on the compound prescription containing cyclodextrin, which can improve the solubility, stability, and pharmacokinetic properties of free PM, and reduces toxicity. Using BCR-ABL(T315I) induced TKI resistance CML mouse model, we demonstrated that PMF could significantly prevent CML disease and diminish survival and maintenance of LSCs. However, PMF treatment alone also increased glutaminolysis of LSCs by increasing GLS1 expression. Treatment of PMF combination with targeting GLS1 can synergistically impede disease and eradicate LSCs of CML. Our findings provide a guidance for PMF clinical trials in the future for TKI resistance CML patients. Download : Download high-res image (276KB) Download : Download full-size image

engineering, biomedical,materials science, biomaterials
Chidamide in Relapsed or Refractory Peripheral T Cell Lymphoma: A Multicenter Real-World Study in China

Yuankai Shi,Bo Jia,Wei Xu,Wenyu Li,Ting Liu,Peng Liu,Weili Zhao,Huilai Zhang,Xiuhua Sun,Haiyan Yang,Xi Zhang,Jie Jin,Zhengming Jin,Zhiming Li,Lugui Qiu,Mei Dong,Xiaobing Huang,Yi Luo,Xiaodong Wang,Xin Wang,Jianqiu Wu,Jingyan Xu,Pingyong Yi,Jianfeng Zhou,Hongming He,Lin Liu,Jianzhen Shen,Xiaoqiong Tang,Jinghua Wang,Jianmin Yang,Qingshu Zeng,Zhihui Zhang,Zhen Cai,Xiequn Chen,Kaiyang Ding,Ming Hou,Huiqiang Huang,Xiaoling Li,Rong Liang,Qifa Liu,Yuqin Song,Hang Su,Yuhuan Gao,Lihong Liu,Jianmin Luo,Liping Su,Zimin Sun,Huo Tan,Huaqing Wang,Jingwen Wang,Shuye Wang,Hongyu Zhang,Xiaohong Zhang,Daobin Zhou,Ou Bai,Gang Wu,Liling Zhang,Yizhuo Zhang

DOI: https://doi.org/10.1186/s13045-017-0439-6

IF: 28.5

2017-01-01

Journal of Hematology & Oncology

Abstract:The efficacy and safety of chidamide, a new subtype-selective histone deacetylase (HDAC) inhibitor, have been demonstrated in a pivotal phase II clinical trial, and chidamide has been approved by the China Food and Drug Administration (CFDA) as a treatment for relapsed or refractory peripheral T cell lymphoma (PTCL). This study sought to further evaluate the real-world utilization of chidamide in 383 relapsed or refractory PTCL patients from April 2015 to February 2016 in mainland China. For patients receiving chidamide monotherapy (n = 256), the overall response rate (ORR) and disease control rate (DCR) were 39.06 and 64.45%, respectively. The ORR and DCR were 51.18 and 74.02%, respectively, for patients receiving chidamide combined with chemotherapy (n = 127). For patients receiving chidamide monotherapy and chidamide combined with chemotherapy, the median progression-free survival (PFS) was 129 (95% CI 82 to 194) days for the monotherapy group and 152 (95% CI 93 to 201) days for the combined therapy group (P = 0.3266). Most adverse events (AEs) were of grade 1 to 2. AEs of grade 3 or higher that occurred in ≥5% of patients receiving chidamide monotherapy included thrombocytopenia (10.2%) and neutropenia (6.2%). For patients receiving chidamide combined with chemotherapy, grade 3 to 4 AEs that occurred in ≥5% of patients included thrombocytopenia (18.1%), neutropenia (12.6%), anemia (7.1%), and fatigue (5.5%). This large real-world study demonstrates that chidamide has a favorable efficacy and an acceptable safety profile for refractory and relapsed PTCL patients. Chidamide combined with chemotherapy may be a new treatment choice for refractory and relapsed PTCL patients but requires further investigation.
Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Yiyu Gu,Xiaoqing Lu,Xiaodong Ma,Haojian Zhang,Yuanyuan Ji,Wanjing Ding,Li Shen

DOI: https://doi.org/10.6023/cjoc201908021

2020-01-01

Abstract:Polypharmacology has emerged as a promising approach to drug discovery, especially antitumor drug. This study reports the design, synthesis, and biological evaluation of novel phosphatidylinositol 3-kinases (PI3Ks) and histone deacetylases (HDACs) dual inhibitors on the basis of GSK2126458 under clinical evaluation and vorinostat approved. Among these hybrid molecules, GYB-4 and GYB-5 possessed potent inhibition against both PI3K alpha (1.0 and 1.3 nmol/L, respectively) and HDAC1 (4.2 and 4.8 nmol/L, respectively). Antiproliferative assays with HCT116, PC3 and A2780 cell lines subsequently were performed. The structure-activity relationship study will guide to optimization of dual PI3K and HDAC inhibitors.
Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma

Yu-bo Zhou,Yang-ming Zhang,Hong-hui Huang,Li-jing Shen,Xiao-feng Han,Xiao-bei Hu,Song-da Yu,An-hui Gao,Li Sheng,Ming-bo Su,Xiao-li Wei,Yue Zhang,Yi-fan Zhang,Zhi-wei Gao,Xiao-yan Chen,Fa-jun Nan,Jia Li,Jian Hou

DOI: https://doi.org/10.1038/s41401-021-00728-y

IF: 7.169

2021-08-02

Acta Pharmacologica Sinica

Abstract:Abstract HDAC inhibitors (HDACis) have been intensively studied for their roles and potential as drug targets in T-cell lymphomas and other hematologic malignancies. Bisthianostat is a novel bisthiazole-based pan-HDACi evolved from natural HDACi largazole. Here, we report the preclinical study of bisthianostat alone and in combination with bortezomib in the treatment of multiple myeloma (MM), as well as preliminary first-in-human findings from an ongoing phase 1a study. Bisthianostat dose dependently induced acetylation of tubulin and H3 and increased PARP cleavage and apoptosis in RPMI-8226 cells. In RPMI-8226 and MM.1S cell xenograft mouse models, oral administration of bisthianostat (50, 75, 100 mg·kg -1 ·d -1 , bid) for 18 days dose dependently inhibited tumor growth. Furthermore, bisthianostat in combination with bortezomib displayed synergistic antitumor effect against RPMI-8226 and MM.1S cell in vitro and in vivo. Preclinical pharmacokinetic study showed bisthianostat was quickly absorbed with moderate oral bioavailability ( F % = 16.9%–35.5%). Bisthianostat tended to distribute in blood with V ss value of 0.31 L/kg. This distribution parameter might be beneficial to treat hematologic neoplasms such as MM with few side effects. In an ongoing phase 1a study, bisthianostat treatment was well tolerated and no grade 3/4 nonhematological adverse events (AEs) had occurred together with good pharmacokinetics profiles in eight patients with relapsed or refractory MM (R/R MM). The overall single-agent efficacy was modest, stable disease (SD) was identified in four (50%) patients at the end of first dosing cycle (day 28). These preliminary in-patient results suggest that bisthianostat is a promising HDACi drug with a comparable safety window in R/R MM, supporting for its further phase 1b clinical trial in combination with traditional MM therapies.

pharmacology & pharmacy,chemistry, multidisciplinary
A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signaling

Ting-Yu Chang,Kunal Nepali,Yi-Ying Chen,Yu-Chen S H Yang,Kai-Cheng Hsu,Yun Yen,Shiow-Lin Pan,Jing-Ping Liou,Sung-Bau Lee,Yu-Chen S.H. Yang

DOI: https://doi.org/10.1016/j.biopha.2021.111485

2021-06-01

Abstract:Aberrant alteration of epigenetic information disturbs chromatin structure and gene function, thereby facilitating cancer development. Several drugs targeting histone deacetylases (HDACs), a group of epigenetic enzymes, have been approved for treating hematologic malignancies in the clinic. However, patients who suffer from solid tumors often respond poorly to these drugs. In this study, we report a selective entinostat derivative, MPT0L184, with potent cancer-killing activity in both cell-based and mouse xenograft models. A time-course analysis of cell-cycle progression revealed that MPT0L184 treatment elicited an early onset of mitosis but prevented the division of cells with duplicated chromosomes. We show that MPT0L184 possessed potent inhibitory activity toward HDAC1 and 2, and its HDAC-inhibitory activity was required for initiating premature mitotic signaling. HDAC inhibition by MPT0L184 reduced WEE1 expression at the transcription level. In addition, MPT0L184 treatment also downregulated ATR-mediated CHK1 phosphorylation independent of HDAC inhibition. Furthermore, gastric cancer cells resistant to HDAC inhibitors were vulnerable to MPT0L184. Taken together, our study discovers MPT0L184 as a novel HDAC inhibitor that can trigger premature mitosis and potentially counteract drug resistance of cancers.

pharmacology & pharmacy,medicine, research & experimental
Histone deacetylase inhibitor and PD‑1 blockade synergistically inhibit B‑cell lymphoma progression in mice model by promoting T‑cell infiltration and apoptosis

Tong Wang,Xu Ye,Hao Jiang,Yu Gao

DOI: https://doi.org/10.3892/or.2024.8792

Abstract:B‑cell lymphoma is difficult to cure because of its biological and clinical heterogeneity, and due to native chemoresistance. Immunotherapies that overcome cancer‑induced immune evasion have been the center of recent developments in oncology. This is emphasized by the accomplishment of various agents that disrupt programmed cell death protein 1 (PD‑1)‑mediated immune suppression in diverse tumors. However, while PD‑1 blockade has been effective in numerous malignancies, a significant proportion of cancers, including B‑cell lymphoma, show certain rates of primary resistance to these therapeutic strategies. Histone deacetylase inhibitors (HDACis) have exhibited anticancer activity though suppressing cell proliferation, inducing differentiation and triggering apoptosis. The present study aimed to explore a therapeutic strategy combining a HDACi (romidepsin) and PD‑1 blockade (BMS‑1) in B‑cell lymphoma, utilizing a constructed mouse model of B‑cell lymphoma. The IC50 of the two inhibitors was confirmed by MTT assay, and their inhibitory effects were revealed to be dose‑ and time‑dependent. The data demonstrated that the combined treatment of romidepsin and BMS‑1 synergistically inhibited the growth of B‑cell lymphoma. Furthermore, it was revealed that romidepsin and BMS‑1 synergistically triggered apoptosis in mouse B‑cell lymphoma. The synergistic effect of these agents was capable of activating tumor‑infiltrating lymphocytes, particularly CD3+CD4+ and CD3+CD8+ T cells. The results of the present study underscore the potential of HDAC inhibition in conjunction with PD‑1 blockade as a novel therapeutic approach for B‑cell lymphoma, highlighting the synergistic effects of these two mechanisms in enhancing antitumor immunity.
Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity

Shunda Li,Chunlong Zhao,Guozhen Zhang,Qifu Xu,Qian Liu,Wei Zhao,C. James Chou,Yingjie Zhang

DOI: https://doi.org/10.1016/j.bioorg.2021.105278

IF: 5.307

2021-11-01

Bioorganic Chemistry

Abstract:Histone deacetylase 6 (HDAC6) is a promising therapeutic target for the treatment of cancers, neurodegenerative diseases and autoimmune disorders. Herein a novel series of pyrrolo[2,3-d]pyrimidine-based HDAC inhibitors were designed, synthesized and biologically evaluated, among which compounds 7a, 12a1, and 16a1 exhibited potent inhibitory activities and selectivities against HDAC6. Notably, compared with the well-known HDAC6 inhibitor Tubastatin A, our pyrrolo[2,3-d]pyrimidine-based HDAC6 inhibitors showed superior in vitro antiproliferative activity against human multiple myeloma cell lines RPMI 8226, U266 and MM.1S, while maintaining the low cytotoxicity against human breast cancer cell line MDA-MB-231 and two normal cell lines. The HDAC6 selective inhibition of one representative compound 12a1 in RPMI 8226 cells was confirmed by western blot analysis. Although pyrrolo[2,3-d]pyrimidine is a privileged structure in many kinase inhibitors, compound 12a1 showed negligible inhibition against several kinases including JAK family members and Akt1, indicating its acceptable off-target profile. Besides, compound 12a1 exhibited desirable metabolic stability in mouse liver microsome. The in vivo anti-multiple myeloma potency of 12a1, alone and in combination with bortezomib, was demonstrated in a RPMI 8226 xenograft model.

biochemistry & molecular biology,chemistry, organic
Design, synthesis and biological evaluation of novel HDACs inhibitors based on pyrrolo[2,3‐d]pyrimidine and pyrrolo[2,3‐b]pyridine scaffolds

Nian-Dong Mao,Yuan Gao,Xia-Wen Dang,Ji-Long Duan,Zi Hui,Hao Che,Yueying Xu,Hang Zhang,Xingrui He,Carmen Garrido,Xiang-Yang Ye

DOI: https://doi.org/10.1002/cmdc.202200683

IF: 3.54

2023-05-03

ChemMedChem

Abstract:Histone deacetylases (HDACs) are validated targets for the development of anticancer drugs in epigenetics. We have designed and synthesized a series of novel HDACs inhibitors based on pyrrolo[2,3‐d]pyrimidine and pyrrolo[2,3‐b]pyridine scaffolds. Compound B3 exhibits potent inhibitory activity against HDAC1 and HDAC6 with IC50 values of 5.2 nM and 4.4 nM, respectively. It exhibited potent anti‐proliferative effects against three tumour cell lines (IC50 = 0.13, 0.37, and 1.11 μM, MV‐4‐11, K562, and WSU‐DLCL‐2 respectively) with 2‐6 fold improvement comparing to SAHA. Mechanistic studies on WSU‐DLCL‐2 cell reveal that B3 exhibits anticancer effects through induction of G0/G1 phase arrest and promotion of apoptosis. The result warrants further investigation of this series of compounds for the treatment of hematological malignancy.

pharmacology & pharmacy,chemistry, medicinal
The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma

Xing Wang,Dedao Wang,Ning Ding,Lan Mi,Hui Yu,Meng Wu,Feier Feng,Luni Hu,Yime Zhang,Chao Zhong,Yingying Ye,Jiao Li,Wei Fang,Yunfei Shi,Lijuan Deng,Zhitao Ying,Yuqin Song,Jun Zhu,Xing Wang,Dedao Wang,Ning Ding,Lan Mi,Hui Yu,Meng Wu,Feier Feng,Luni Hu,Yime Zhang,Chao Zhong,Yingying Ye,Jiao Li,Wei Fang,Yunfei Shi,Lijuan Deng,Zhitao Ying,Yuqin Song,Jun Zhu

DOI: https://doi.org/10.3390/cancers13174249

2021-08-24

Cancers

Abstract:Background: Upregulation of H3K27me3 induced by EZH2 overexpression or somatic heterozygous mutations were implicated in lymphomagenesis. It has been demonstrated that several EZH2-target agents have notable therapeutic effects in EZH2-mutant B-cell lymphoma patients. Here we present a novel highly selective EZH2 inhibitor SHR2554 and possible combination strategy in diffuse large B-cell lymphoma (DLBCL). Methods: Cell proliferation, cell cycle and apoptosis were analyzed by CellTiter-Glo Luminescent Cell Viability Assay and flow cytometry. Western Blot was used to detect the expression of related proteins. The gene expression profiling post combination treatment was analyzed by RNA-Seq. Finally, CDX and PDX models were used to evaluate the synergistic anti-tumor effects of the combination treatment in vivo. Results: The novel EZH2 inhibitor SHR2554 inhibited proliferation and induced G1 phase arrest in EZH2-mutant DLBCL cell lines. The combination of EZH2 inhibitor SHR2554 with histone deacetylase (HDAC) inhibitor chidamide (hereafter referred to as HBI8000) exerted synergistic anti-proliferative activity in vitro and in vivo. Gene expression profile analysis revealed dramatic inhibition of the DNA replication process in combined treatment. Conclusions: SHR2554, a potent, highly selective small molecule inhibitor of EZH2, inhibited EZH2-mutant DLBCL more significantly in vitro and in vivo. The combination of HDAC inhibitor HBI8000 with EZH2 inhibitor SHR2554 exhibited dramatic anti-tumor activity in both mutant and wild-type DLBCL, which may become a potential therapeutic modality for the treatment of DLBCL patients.

oncology
Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors

Ping-Ting Mao,Wei-Bao He,Xi Mai,Li-Hua Feng,Na Li,Yi-Jing Liao,Cai-Sheng Zhu,Jian Li,Ting Chen,Shu-Hao Liu,Qi-Ming Zhang,Ling He

DOI: https://doi.org/10.1016/j.bmc.2021.116599

2022-02-01

Abstract:The aminobenzamide is selective to class I histone deacetylases (HDACs) and displays unique tight-binding/slow-off HDAC-binding mechanism. Herein, we report a series of 9-substituted purine aminobenzamides that selectively inhibit class I HDACs. The activities in vitro showed compound 9d exhibited 12 folds more potent than MS-275 against HDAC1 isoform and showed excellent inhibitory activity on cancer cells, including HCT-116, MDA-MB-231, K562 cell lines. The metabolic stability of 9d was much better than that of the well-known HDAC inhibitor SAHA. Pulse exposure test of western blot assay demonstrated that 9a, 9d induced histone acetylation in a similar manner to MS-275. Further biological validation demonstrated that 9d prevented cell transition from G1 phase to S phase by reducing Cyclin D1, CDK2 and lifting p21, induced early apoptosis by upregulating BAX and downregulating Bcl-2 in HCT-116 cells.

biochemistry & molecular biology,chemistry, medicinal, organic
Targeting HDACs for diffuse large B-cell lymphoma therapy

Chunyan Wu,Qiao Song,Sophie Gao,Shaoling Wu

DOI: https://doi.org/10.1038/s41598-023-50956-x

IF: 4.6

2024-01-03

Scientific Reports

Abstract:Histone deacetylases (HDACs) are involved in tumorigenesis and progression, however, their role in diffuse large B-cell lymphoma (DLBCL) is not well understood. In this study, we examined the expression levels, mutations, and clinical significance of HDACs in DLBCL. Additionally, we investigated the therapeutic potential of Chidamide, a novel HDAC inhibitor, to provide scientific evidence for targeting HDACs in DLBCL patients. We extracted transcriptome data of DLBCLs––including 47 lymph node samples and 337 whole-blood-cell controls––from The Cancer Genome Atlas. Bioinformatic analyses of HDAC expression, mutation, and correlation with the clinical significance of DLBCL patients were performed with the Gene Expression Profiling Interactive Analysis, GENEMANIA, and web-based software including cBioPortal and WebGestalt. To examine the therapeutic effect of Chidamide, DLBCL cell lines (WSU-DLCL-2 and DB cells) were employed. Cell proliferation and apoptosis were analyzed with Cell Counting Kit-8 and flow cytometry assays. The impact of Chidamide treatment was also analyzed by RNA sequencing of treated DB cells. Western blot was used to explore the molecular mechanism of the cytotoxicity of Chidamide on DLBCL cell lines. The expression of some HDACs (HDAC1, 2, 3, 4, 6, 7, 8, and 9) were significantly higher in the lymph node samples of DLBCL than that in whole-blood-cell controls. Moreover, we found that the mutation rate of HDACs was also higher in DLBCL tissues, although the overall survival of DLBCL patients was not associated with HDAC expression. Chidamide was found to have a cytotoxic effect on DLBCL cells in a dose-dependent manner, while transcriptome analysis and western blot revealed that using it for treatment impacted several biological processes, including PI3K/AKT signaling, mTOR signaling, the cell cycle, and apoptosis pathways. Alterations of HDAC genes, including enhanced expression and mutations, are positively related to DLBCL. Targeting HDACs with specific inhibitors such as Chidamide may represent a potential therapeutic approach for DLBCL patients.

multidisciplinary sciences
Design, synthesis, and evaluation of antitumor activity of 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives as PD-1/PD-l1 inhibitors

Feng Zhang,Hua Zhang,Shijia Zhou,Jacek Plewka,Ming Wang,Shishi Sun,Caiyun Wu,Qimeng Yu,Mengyu Zhu,Annoor Awadasseid,Yanling Wu,Katarzyna Magiera-Mularz,Wen Zhang

DOI: https://doi.org/10.1016/j.ejmech.2024.116683

IF: 7.088

2024-07-21

European Journal of Medicinal Chemistry

Abstract:A series of novel 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives was designed, synthesized, and evaluated for their antitumor effects as PD-1/PD-L1 inhibitors both in vitro and in vivo . Firstly, the ability of these compounds to block the PD-1/PD-L1 immune checkpoint was assessed using the homogeneous time-resolved fluorescence (HTRF) assay. Two of the compounds can strongly block the PD-1/PD-L1 interaction, with IC 50 values of less than 10 nM, notably, compound HD10 exhibited significant clinical potential by inhibiting the PD-1/PD-L1 interaction with an IC 50 value of 3.1 nM. Further microscale thermophoresis (MST) analysis demonstrated that HD10 had strong interaction with PD-L1 protein. Co-crystal structure (2.7 Å) analysis of HD10 in complex with the PD-L1 protein revealed a strong affinity between the compound and the target PD-L1 dimer. This provides a solid theoretical basis for further in vitro and in vivo studies. Next, a typical cell-based experiment demonstrated that HD10 could remarkably prevent the interaction of hPD-1 293 T cells from human recombinant PD-L1 protein, effectively restoring T cell function, and promoting IFN-γ secretion in a dose-dependent manner. Moreover, HD10 was effective in suppressing tumor growth (TGI = 57.31 %) in a PD-1/PD-L1 humanized mouse model without obvious toxicity. Flow cytometry, qPCR, and immunohistochemistry data suggested that HD10 inhibits tumor growth by activating the immune system in vivo . Based on these results, it seems likely that HD10 is a promising clinical candidate that should be further investigated.

chemistry, medicinal
Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo

Yuqi Jiang,Jie Xu,Kairui Yue,Chao Huang,Mengting Qin,Dongyu Chi,Qixin Yu,Yue Zhu,Xiaohan Hou,Tongqiang Xu,Min Li,C. James Chou,Xiaoyang Li

DOI: https://doi.org/10.1021/acs.jmedchem.1c01472

IF: 8.039

2021-12-23

Journal of Medicinal Chemistry

Abstract:As "Michael acceptors" may induce promiscuous responses in mammalian cells by reacting with various proteins, we modified the cinnamamide of our previous hydrazide-based HDAC inhibitors (HDACIs) to deactivate the Michael reaction. Representative compound 11h is 2-5 times more potent than lead compound 17 in both HDAC inhibitory activity (IC50 = 0.43-3.01 nM) and cell-based antitumor assay (IC50 = 19.23-61.04 nM). The breakthrough in the pharmacokinetic profile of 11h (oral bioavailability: 112%) makes it a lead-in-class oral active agent, validated in the in vivo anti-AML study (4 mg/kg p.o., TGI = 78.9%). Accumulated AcHH3 and AcHH4 levels in tumor tissue directly correlate with the in vivo efficacy, as panobinostat with lower AcHH3 and AcHH4 levels than 11h displays limited activity. To the best of our knowledge, this work contributes the first report of in vivo antitumor activity of hydrazide-based HDACIs. The outstanding pharmacokinetic/pharmacodynamic and antitumor activity of 11h could potentially extend the clinical application of current HDACIs.

chemistry, medicinal
A promising natural product in diffuse large B-cell lymphoma therapy by targeting PIM1

Xinyun Zhang,Qi Su,Yuchen Zhang,Rong Rong,Si Chen,Lexin He,Wenzhuo Zhuang,Bingzong Li

DOI: https://doi.org/10.1007/s00277-024-05670-7

Abstract:Diffuse large B-cell lymphoma (DLBCL) is the most common and aggressive type of B-cell lymphoma. Unfortunately, about one-third of patients either relapse after the initial treatment or are refractory to first-line therapy, indicating a need for new treatment modalities. PIM serine/threonine kinases are proteins that are associated with genetic mutations, overexpression, or translocation events in B-cell lymphomas. We conducted an integrative analysis of whole-exome sequencing in 52 DLBCL patients, and no amplification, mutation, or translocation of the PIM1 gene was detected. Instead, analyses of TCGA and GTEx databases identified that PIM1 expression was increased in DLBCL samples compared to normal tissue, and high expression levels were associated with poor overall survival. Moreover, interference of PIM1 significantly suppressed DLBCL cell proliferation. In addition, we identified anwulignan, a natural small-molecule compound, as a PIM1 inhibitor. Anwulignan directly binds to PIM1 and exerts antitumor effects on DLBCL in vitro and in vivo by inducing apoptosis, cell cycle arrest, and autophagic cell death. Furthermore, we identified an effective synergistic combination between anwulignan and chidamide. Our findings suggested that PIM1 could be a therapeutic target and prognostic factor for DLBCL, and anwulignan holds promise for future development as a natural product for treatment.
Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment

Yichen Sun,Jing Han Hong,Zhiqiang Ning,Desi Pan,Xin Fu,Xianping Lu,Jing Tan

DOI: https://doi.org/10.3389/fphar.2022.932914

IF: 5.6

2022-09-02

Frontiers in Pharmacology

Abstract:Histone deacetylase (HDAC) is one of the most characterized epigenetic modifiers, modulating chromatin structure and gene expression, which plays an important role in cell cycle, differentiation and apoptosis. Dysregulation of HDAC promotes cancer progression, thus inhibitors targeting HDACs have evidently shown therapeutic efficacy in multiple cancers. Tucidinostat (formerly known as chidamide), a novel subtype-selective HDAC inhibitor, inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10. Tucidinostat is approved in relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL), advanced breast cancer and R/R adult T-cell leukemia-lymphoma (ATLL). Compared with other HDAC inhibitors, tucidinostat shows notable antitumor activity, remarkable synergistic effect with immunotherapy, and manageable toxicity. Here, we comprehensively summarize recent advances in tucidinostat as both monotherapy and a regimen of combination therapy in both hematological and solid malignancies in clinic. Further studies will endeavor to identify more combination strategies with tucidinostat and to identify specific clinical biomarkers to predict the therapeutic effect.

pharmacology & pharmacy
A Novel Mechanism of Action of Histone Deacetylase Inhibitor Chidamide: Enhancing the Chemotaxis Function of Circulating PD-1(+) Cells From Patients With PTCL

Chong Wei,Shaoxuan Hu,Mingjie Luo,Chong Chen,Wei Wang,Wei Zhang,Daobin Zhou

DOI: https://doi.org/10.3389/fonc.2021.682436

IF: 4.7

2021-06-01

Frontiers in Oncology

Abstract:Background Peripheral T‐cell lymphomas (PTCLs) are a heterogeneous group of neoplasms characterized by a poor prognosis. Histone deacetylase (HDAC) inhibitors have emerged as novel therapeutic agents for PTCLs. In this study, we aimed to explore the immunomodulatory effect of the HDAC inhibitor chidamide on circulating PD-1(+) cells from patients with PTCL, as well as its correlation with treatment response. Methods We enrolled newly diagnosed patients with PTCLs treated with a combination of chidamide and chemotherapy. Gene expression profile analysis was performed on peripheral blood PD-1(+) cells, both at baseline and at the end of treatment. A list of differentially expressed genes (DEGs) was identified. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed to annotate the biological implications of the DEGs. A gene concept network was constructed to identify the key DEGs for further PCR verification. Results A total of 302 DEGs were identified in the complete remission (CR) group, including 162 upregulated and 140 downregulated genes. In contrast, only 12 DEGs were identified in the non-CR group. GO analysis revealed that these upregulated DEGs were mainly involved in chemokine activity, cell chemotaxis, and cellular response to interleukin-1 and interferon-γ. Furthermore, KEGG pathway analysis showed that these DEGs were enriched in cytokine-cytokine receptor interaction and chemokine signaling pathways. The innate immune signaling pathways, including the Toll-like and NOD-like receptor signaling pathways, were also influenced. The gene concept network revealed that the key upregulated genes belonged to the C-C chemokine family. Conclusion Our results showed that chidamide treatment notably enhanced the expression of genes associated with chemokine activity and chemotaxis function of circulating PD-1(+) cells. By recruiting immune cells and improving the innate immune function of PD-1(+) cells, chidamide may reshape the tumor microenvironment to an anti-tumor phenotype and synergize with checkpoint inhibitors.

oncology
Phase Ii Study of Chidamide (cs055), A New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Yuan-Kai Shi,Mei Dong,Xiao-Nan Hong,Wei-Jing Zhang,Feng,Jun Zhu,Li Yu,Xiao-Yan Ke,Hui-Qiang Huang,Zhi-Xiang Shen,Yun Fan,Wei Li,Xie-Lan Zhao,Lu-Gui Qiu,He Huang

DOI: https://doi.org/10.1200/jco.2013.31.15_suppl.8525

IF: 45.3

2013-01-01

Journal of Clinical Oncology

Abstract:8525 Background: Chidamide (CS055) is a new benzamide type of histone deacetylase (HDAC) inhibitor with subtype selective activity against HDAC1, 2, 3 and 10. Chidamide has shown well-tolerated and favorable PK profiles in patients (pts) with advanced solid tumors and lymphomas. This phase II study was to evaluate the efficacy and safety of chidamide in relapsed or refractory peripheral T-cell lymphoma (PTCL). Methods: 102 PTCL pts were enrolled. In the exploratory trial, pts were randomized to receive chidamide 30mg or 50mg twice per week for 2 weeks, followed by 1 week of rest. In the pivotal trial, chidamide was administered 30mg twice per week w/o drug-free holiday. The primary endpoint was overall response rate (ORR). Responses were assessed using IWC criteria. Results: In the exploratory trial, 19 pts were enrolled with 9 and 10 to the 30mg and 50mg arms, respectively. ORR was 11.1% (1 CR) in the 30mg arm and 40.0% (1 CR, 1 CRu, 2 PR) in the 50mg arm. One pt in the 50mg arm experienced drug-related grade 4 thrombocytopenia. In the pivotal trial, 83 pts were enrolled. Most pts were stage III (35.2%) or IV (45.9%). 23 pts (29.1%) had confirmed responses out of 79 evaluable pts in the pivotal trial (8 CR, 3 CRu, and 12 PR). Responses of 19 pts (24.1%) maintained for ≥12 weeks. ORR with 27.8% was obtained by the Independent Review Committee. 68 pts (81.9%) experienced at least 1 AE in the pivotal trial, with 52.9% of AEs ≤ grade 2. The most common AEs were thrombocytopenia (50.6%), leucocytopenia (39.8%), neutropenia(21.7%), and fatigue (9.6%). 1 pt had a grade 3 QTc prolongation. 7 pts (8.4%) experienced at least one SAE, in which a grade 4 thrombocytopenia was considered to be drug-related. 2 pts with responses (CR) have received chidamide for > 43 months w/o evidence of cumulative toxicity. Conclusions: Chidamide as an oral single agent had significant and durable activity in pts with relapsed or refractory PTCL. Toxicities with the therapy were generally tolerable and manageable. The overall differences in pathological subtypes of pts enrolled and clinical profiles between chidamide and the two existing drugs, pralatrexate and romidepsin, will be discussed. Clinical trial information: ChiCTR-TNC-10000811.

[Neurodegenerative disorders and the role of trinucleotide repeat expansion. II. Molecular genetics].

HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIa trial.

Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model

The Novel Histone Deacetylase Inhibitor Pracinostat Suppresses the Malignant Phenotype in Human Glioma

HDAC I/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells

Chidamide in Relapsed or Refractory Peripheral T Cell Lymphoma: A Multicenter Real-World Study in China

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma

A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signaling

Histone deacetylase inhibitor and PD‑1 blockade synergistically inhibit B‑cell lymphoma progression in mice model by promoting T‑cell infiltration and apoptosis

Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity

Design, synthesis and biological evaluation of novel HDACs inhibitors based on pyrrolo[2,3‐d]pyrimidine and pyrrolo[2,3‐b]pyridine scaffolds

The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma

Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors

Targeting HDACs for diffuse large B-cell lymphoma therapy

Design, synthesis, and evaluation of antitumor activity of 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives as PD-1/PD-l1 inhibitors

Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo

A promising natural product in diffuse large B-cell lymphoma therapy by targeting PIM1

Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment

A Novel Mechanism of Action of Histone Deacetylase Inhibitor Chidamide: Enhancing the Chemotaxis Function of Circulating PD-1(+) Cells From Patients With PTCL

Phase Ii Study of Chidamide (cs055), A New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma